Mistaken Identity: A Prevalence Study of Bromazolam in the American Great Lakes Region
- 3 July 2026
- journal article
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (14) , 2881-2887
Abstract
Bromazolam (BRZ) is a novel psychoactive substance benzodiazepine drug that has recently emerged within the illicit drug supply in the United States. BRZ is not FDA-approved and is distributed in drug mixtures or as counterfeit "Xanax". We explored the BRZ prevalence from oral fluid samples submitted to our lab for testing. BRZ-positive sample results were examined between August 2024 and November 2025. Illicit drug and other benzodiazepine content, medication lists, and associated county data were also gathered to indicate prevalence, identify use trends, and map BRZ use. BRZ was found in 219 of 4,579 samples that screened positive for benzodiazepines (4.8%). Approximately half (109, 49.8%) of cases contained at least one illicit substance. A subset of samples (45, 20.5%) listed at least one prescription benzodiazepine; many of these samples reported negative for the listed medication (17, 37.8%). BRZ use was widespread in the Great Lakes region, but declined in prevalence over time. BRZ was found with illicit drugs as well as by itself, presenting a challenge in clinical settings relying on instant screening devices for benzodiazepine compliance. The observed decline in BRZ use may indicate a possible shift in drug use trends.Keywords
This publication has 27 references indexed in Scilit:
- Detected substances among patients with confirmed bromazolam exposure who present to the emergency department following a suspected opioid and/or stimulant-related non-fatal overdoseDrug and Alcohol Dependence, 2025
- A Mixed-Methods Study of Motives for Benzodiazepine Misuse Among Adults Receiving Substance Use Disorder TreatmentSubstance Use & Misuse, 2025
- Detection of the benzodiazepine bromazolam by liquid chromatography with quadrupole time of flight mass spectrometry in postmortem toxicology casework and prevalence in Indiana (2023)Journal of Analytical Toxicology, 2024
- Flubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and BromazolamJournal of Analytical Toxicology, 2020
- Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017Clinical Toxicology, 2018
- Interpreting oral fluid drug results in prisoners: monitoring current drug intake and detection times for drugs self-administered prior to detentionForensic Toxicology, 2018
- The emergence of new psychoactive substance (NPS) benzodiazepines: A reviewDrug Testing and Analysis, 2017
- Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administrationForensic Science International, 2016
- Comparison of drug concentrations between whole blood and oral fluidDrug Testing and Analysis, 2013
- 6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activityJournal of Medicinal Chemistry, 1979